Precipio Inc (NASDAQ:PRPO) saw a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 670,802 shares, a drop of 55.1% from the January 15th total of 1,494,113 shares. Based on an average daily volume of 1,502,323 shares, the short-interest ratio is presently 0.4 days. Currently, 2.5% of the shares of the stock are sold short.
Shares of PRPO opened at $0.17 on Thursday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.13 and a current ratio of 0.14. Precipio has a 12 month low of $0.15 and a 12 month high of $1.75.
Precipio (NASDAQ:PRPO) last issued its quarterly earnings data on Monday, November 19th. The biotechnology company reported ($0.13) EPS for the quarter. Precipio had a negative net margin of 610.39% and a negative return on equity of 149.24%. The business had revenue of $0.65 million during the quarter.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by BBNS and is the property of of BBNS. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://baseballnewssource.com/2019/02/14/short-interest-in-precipio-inc-prpo-decreases-by-55-1/3214948.html.
Precipio, Inc, a cancer diagnostics company, provides diagnostic products and services to the oncology market. It also develops a platform to eradicate the problem of misdiagnosis within academic institutions. In addition, the company delivers diagnostic information to physicians and their patients. It has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, as well as PerkinElmer.
Further Reading: Why is the ex-dividend date different from the record date?
Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with MarketBeat.com's FREE daily email newsletter.